Advertisements

Tebonin Forte

Quick links to important sections

Tebonin Forte

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Tebonin Forte

Property Description
Active ingredient Standardized Ginkgo biloba dry extract (EGb 761)
Form Film-coated tablets
Pharmacological class Phytopharmaceutical, Nootropic, Vasoregulatory agent
Common general purpose Support for cerebral function and microcirculation
Origin / Manufacturer Natural origin / Manufactured by Dr. Willmar Schwabe GmbH & Co. KG (Germany)
Distinction Contains the patented and clinically studied EGb 761 extract.

What Type of Medicine is Tebonin Forte and Its Composition?

Tebonin Forte is defined as a specialized phytopharmaceutical preparation, signifying its origin as an evidence-based medicine sourced from the Ginkgo biloba tree. Manufactured by Dr. Willmar Schwabe GmbH & Co. KG, this product is delivered in the form of film-coated tablets for oral administration and is categorized as a nootropic and vasoregulatory agent. It is distinct because it is a monopreparation that uses the patented EGb 761 extract as its sole active component.

The EGb 761 extract is not a simple powdered herb but a highly standardized dry extract of Ginkgo biloba leaves. This standardization guarantees a precise concentration of the key chemical substances, including flavone glycosides and terpene lactones (bilobalide and ginkgolides), a critical factor for consistent efficacy. This defined composition is necessary to meet the quality and safety standards of a medicinal product.

General Purpose and Benefit of the Preparation

The general purpose of the preparation is directly linked to its clinically recognized mechanisms of action. Tebonin Forte is intended to support the efficiency of the body's microcirculation, which is crucial for maintaining adequate blood supply, particularly to the brain. Furthermore, the EGb 761 extract provides an antioxidant action, assisting in the protection of cells from oxidative damage.

These physiological actions define the preparation's generalized benefit, which is centered on supporting stable cerebral function and maintaining the integrity of microvascular structures throughout the body.

Regulatory References

  1. EMA Herbal Monograph on Ginkgo biloba L., folium
Advertisements

What side effects are possible with Tebonin Forte?

The safety profile for the standardized Ginkgo biloba dry extract (EGb 761) is established through clinical studies and regulatory documentation, classifying potential reactions primarily by frequency and the body system affected.

Adverse Reactions and Frequency Classification

Adverse effects are documented within standard System-Organ Classes. Those reactions most often reported are classified as Common (may affect up to 1 in 10 people), and include:

  • Nervous System Disorders: Headache, Dizziness.
  • Gastrointestinal Disorders: Nausea, Diarrhea, Stomach upset.
  • Immune System Disorders: Allergic skin reactions (e.g., redness, swelling).

Reactions reported post-marketing, such as those related to bleeding, are typically classified as Rare or of Frequency Not Known.

Serious Safety Considerations

The official regulatory documents highlight the potential for serious adverse reactions, notably an increased risk of bleeding (hemorrhage), particularly when used with antiplatelet agents or anticoagulants. Furthermore, the possibility of the onset of further seizures in patients with a history of epilepsy cannot be excluded.

Population-Specific Restrictions

Use of the preparation is subject to specific restrictions defined in regulatory documents:

  • Contraindications: The medicine is contraindicated in pregnancy due to the potential for increased bleeding tendency. It is also contraindicated for individuals with known hypersensitivity to the extract or its components.
  • Cautions: Caution is advised in patients with a pathologically increased bleeding tendency (haemorrhagic diathesis) and in patients with epilepsy.

Due to the potential for increased bleeding, regulatory guidelines mandate that the medicine be discontinued as a precaution 3 to 4 days prior to any surgical procedure.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Tebonin Forte

Overdose scope

Category Official Regulatory Statement / Entity
Documented overdose presentations Gastrointestinal upset, including nausea, vomiting, or diarrhea, headache, dizziness, and allergic skin reactions (e.g., skin rash or hives).
Physiological systems affected Nervous System (risk of seizures), Hematologic System (risk of bleeding/hemorrhage), Cardiovascular System (arrhythmia/palpitation risk).
Dose-related or exposure-related factors Severe outcomes are associated with intake of high quantities or ingestion of the toxic, unprocessed plant material (raw or roasted seeds).
Population-specific overdose notes Children are especially susceptible to the documented toxicity of the raw Ginkgo seeds, which are poisonous and have been linked to seizures.
Emergency-response statements Contact a poison control center or seek emergency medical attention at once for any suspected overdose.
When immediate medical help is required Immediate help is required if serious or life-threatening symptoms appear, such as uncontrolled or unusual bleeding, signs of a severe allergic reaction, or seizures.

Overdose classifications (high-level)

Category Official Regulatory Statement / Entity
Severity classification Overdose risk includes potentially life-threatening effects, specifically related to hemorrhage and neurological symptoms.
Regulatory basis Information is based on official EMA, NIH, and national regulatory warnings regarding Ginkgo biloba extract.
Overdose-context constraints No specific antidote for the extract is officially known; management is limited to symptomatic and supportive treatment.

Resulting overdose structure

Official overdose statements:

  • Officially documented severe manifestations include an increased susceptibility to bleeding, carrying the risk of intracranial hemorrhage, and the occurrence of seizures linked to high-quantity ingestion.
  • The regulatory standard is to seek emergency care for any suspected overdose or for the appearance of life-threatening events, such as persistent bleeding, arrhythmia, or a severe allergic reaction.
  • No specific antidote is documented for the extract; therefore, the required medical procedure is symptomatic and supportive treatment.

Connection to the overall overdose profile: Regulatory documents define the overdose profile primarily through the potential for severe hemorrhagic and neurological events, which constitute the core documented toxicity risks. These critical risks establish the mandatory instruction for immediate contact with emergency services or a poison control center, dictating the required response when exposure exceeds the non-toxic threshold.

Advertisements

Therapeutic Uses of Tebonin Forte

Tebonin Forte may be relevant for addressing symptoms related to age-associated mild cognitive impairment and certain chronic, symptomatic circulatory domains.

This medication may be part of symptomatic management in situations where patients experience:

  • Mild Cognitive Symptoms: Used for managing symptoms related to age-related decline in mental performance such as forgetfulness and reduced concentration.
  • Neurosensory Symptoms: Applied in addressing issues like persistent ringing in the ears (tinnitus) and episodes of dizziness (vertigo).
  • Circulatory Discomfort: Relevant for easing symptoms of minor peripheral circulation problems, including coldness or numbness in the extremities.

This focus on supportive management contributes to easing the overall symptom load and helps maintain functional stability. The preparation is relevant for addressing age-associated cognitive impairment and symptoms related to minor circulatory disorders.


Quick Fact: Relief for Age-Related Symptoms

This medication is commonly used during phases where patients experience noticeable, recurrent symptoms associated with aging that interfere with routine activities, providing supportive assistance in symptom stabilization.

Advertisements

Eligibility and Restrictions for Use

The eligibility for Tebonin Forte is strictly governed by regulatory documentation, which defines who is authorized, restricted, or prohibited from using the medicine. The indicated population for use is adults and older people (18 years and above).


Absolute Contraindications

Population Group Eligibility Status
Pregnant Women Contraindicated
Hypersensitivity Contraindicated in individuals allergic to Ginkgo biloba or excipients.
Excipient Intolerances Contraindicated (e.g., lactase deficiency, due to tablet formulation).

Restricted or Not Recommended Use

Population Group Eligibility Status
Children & Adolescents Not recommended for those under 18 years of age due to insufficient data.
Breastfeeding Women Not recommended as the risk to the infant is unknown.
Bleeding Risk / Epilepsy Use requires caution in patients with bleeding disorders or epilepsy.

Eligibility-Related Restrictions: Patients scheduled for surgery are advised to discontinue the product at least two weeks prior to the procedure. These formal classifications define eligibility based on developmental status, known allergic risks, and comorbidities, as stated in official product information.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the standardized Ginkgo biloba dry extract (EGb 761) found in Tebonin Forte, as described in government regulatory documents.

Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Constraint
Pharmacodynamic Anticoagulants (e.g., Warfarin, Phenprocoumon), Antiplatelet drugs Potential for increased susceptibility to bleeding.
Pharmacokinetic Efavirenz Co-administration is not recommended due to potential for decreased plasma concentration of Efavirenz via CYP3A4 induction.
Pharmacokinetic Dabigatran etexilate (P-gp substrate) Risk of increased systemic exposure due to potential P-glycoprotein (P-gp) inhibition.
Pharmacokinetic Nifedipine The maximum plasma concentration (Cmax) may be increased.

Regulatory Restrictions and Timing

In addition to drug-drug interactions, regulatory documents impose specific constraints. The product must be discontinued as a precaution 3 to 4 days prior to surgery due to the documented potential for bleeding effects. Furthermore, the onset of further seizures in patients with epilepsy cannot be excluded when taking Ginkgo preparations, representing a population-specific interaction caution.

Advertisements

Mechanism of Action

The mechanism of action for the standardized Ginkgo biloba extract (EGb 761) involves multiple cellular and systemic targets, primarily in cerebral and peripheral microvasculature and nervous tissue. The extract's terpene lactones, specifically ginkgolides, function as non-competitive antagonists of the platelet-activating factor (PAF) receptor. This antagonism inhibits PAF-mediated platelet aggregation and reduces local inflammatory responses within the vessel walls.

Simultaneously, the flavonoid glycoside components scavenge reactive oxygen species (ROS), acting as free radical quenchers to attenuate oxidative damage to neuronal and endothelial cell membranes. This activity helps preserve mitochondrial function, promoting high-energy phosphate (ATP) production critical for cellular maintenance. Further intracellular effects include the modulation of multiple neurotransmitter systems, such as the inhibition of monoamine oxidase A (MAO-A), which consequently increases synaptic concentrations of monoamines like dopamine. Additionally, components are implicated in the up-regulation of antioxidant enzymes, leading to reduced overall oxidative stress within the central nervous system. The net system-level physiological consequence is enhanced cerebral microcirculation and modulation of neurotransmission.

Advertisements

Dosage and Administration Information

Tebonin Forte is a proprietary medicinal preparation based on the standardized Ginkgo biloba dry extract, EGb 761. Its administration and dosage are established to standardize use and compliance.


Official Dosing and Administration

Administration is designated solely by the oral route. The standard total daily dose for adults is set between 120 mg and 240 mg of the standardized extract. This quantity is typically taken in a single dose (for 240 mg formulations) or as divided doses (such as twice daily).

Administration Parameter Official Labeled Instruction
Route of Use Oral ingestion only.
Timing & Preparation Taken independently of meals. Tablets must be swallowed whole with sufficient liquid while the user is in an upright position.
Duration of Use Treatment is generally maintained for a minimum course of at least eight weeks. Continuation of use is subject to professional review if no change is noted after three months.
Missed Dose Rule If a dose is missed, the patient should skip it and take the next dose at the regularly scheduled time; do not take a double dose to compensate.

Population-Specific Usage Rules

Use of the EGb 761 preparation is not recommended for children and adolescents under 18 years of age. Standard adult dosage guidelines are maintained for the general population, with no specific adjustments for renal or hepatic impairment.


Connection to the overall use protocol: This procedural structure outlines the precise method for using the medicine, ensuring compliance with established instructions. The defined dose and duration establish a long-term commitment for users 18 years and older to correctly integrate the medicine into their daily routine.

Advertisements

Recent Clinical Evidence

Tebonin Forte: Recent Clinical Evidence

Evidence for Age-Associated Cognitive Symptoms

Research exploring how symptoms change over time in conditions characterized by functional limitations, such as age-related decline in mental performance, often relies on combining data from many individual studies. These studies were primarily randomized, placebo-controlled clinical trials (RCTs). The research examined populations including older adults diagnosed with Mild Cognitive Impairment or mild dementia, including Alzheimer’s disease and vascular dementia, as part of their studies. Studies explored outcomes related to functional imbalance, measuring changes in cognitive function scores, Activities of Daily Living (ADL), and the clinician's global assessment of the patient’s overall condition. Findings from these aggregated trials describe patterns observed in the studies, including the evaluation of scores compared to placebo over defined time intervals. The evidence quality varies, and data for long-term effects are not fully established, meaning the durability of any observed patterns over many years remains uncertain.

Evidence for Tinnitus and Dizziness (Neurosensory Symptoms)

The research evaluated the EGb 761 extract in patients with persistent ringing in the ears (chronic tinnitus) and those with dizziness or vertigo. This evidence is derived mainly from short-term RCTs and studies examining patient-reported experiences. The studies explored outcomes related to patient-reported outcomes describing perceived discomfort, primarily measuring changes in tinnitus severity scores and the frequency or intensity of dizziness episodes. Findings were mixed across studies, and some authoritative reviews indicate limited evidence supporting a consistent change in symptom measurement. Follow-up durations were limited, meaning comparative evidence is lacking, and the clinical relevance of the measured differences remains uncertain.

Evidence for Minor Peripheral Circulatory Problems

The extract was also studied for use in conditions marked by functional limitations, specifically minor peripheral circulation problems such as intermittent claudication (leg pain or coldness during walking). This research explored short-term symptom changes using RCTs where the main outcome monitored was a patient's pain-free walking distance on a treadmill. Data show patterns related to these functional outcomes, but the findings indicate that this change was modest.

Long-Term Studies and Durability of Effect

Evidence contributes to understanding symptom patterns over defined time intervals, but research exploring short-term symptom changes dominates the evidence landscape. For key indications like age-associated cognitive symptoms, trials were typically conducted and reported over a period of up to six months. The research does not fully establish the long-term effects of continued use or the evolution of observations after the study period ends.

Key Studies & References Ginkgo biloba for intermittent claudication (Cochrane Review)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tebonin Forte (FAQ)


Q: Is Tebonin Forte the same as Ginkgo Biloba supplements I can buy over the counter?

Official product information describes Tebonin Forte as a proprietary medicinal preparation containing the highly-standardized EGb 761 extract. Unlike many conventional Ginkgo supplements, preparations approved as a medicine must meet pharmaceutical quality, safety, and efficacy standards set by regulatory bodies. This classification means its composition and use are subject to more stringent oversight than standard dietary supplements.


Q: What conditions does Tebonin Forte officially treat?

According to regulatory documents, the preparation is officially indicated for treating symptoms associated with chronic circulatory and peripheral circulatory disorders. This includes age-related decline in concentration and memory, as well as neurosensory symptoms like persistent tinnitus (ringing in the ears) and dizziness.


Q: Does Tebonin Forte interact with common pain relievers like ibuprofen?

Yes, official product labeling indicates a potential interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes common pain relievers like ibuprofen. Combining the medicine with NSAIDs may increase the potential risk of bleeding or bruising. This warning is due to the extract's effect on blood clotting.


Q: Does the scientific evidence supporting Tebonin Forte show consistent results?

Evidence from clinical studies shows varying results depending on the condition being examined. For example, while studies support its use for age-related cognitive issues, research results for conditions like tinnitus are often described as mixed or modest by authoritative reviews. Regulatory sources acknowledge this range in reported outcomes, but the preparation remains approved for its stated indications.


Q: Does Tebonin Forte contain any gluten or common allergens?

The excipients (inactive ingredients) in the tablets include lactose. Consequently, official guidance states that the medicine is contraindicated for individuals with known lactose intolerance, lactase deficiency, or glucose-galactose malabsorption syndrome. Product information does not typically specify common allergens like gluten, but a review of the full list of excipients is recommended for patients with sensitivities.


Q: Are there specific times of day that are better for taking Tebonin Forte?

For regimens requiring a divided dose, official instructions generally recommend taking one tablet in the morning and the second tablet in the evening. Regulatory documents specify that the tablets can be taken independently of meals.


Q: If I am taking medication for depression, can I also take Tebonin Forte?

Caution is officially advised regarding co-administration with certain types of antidepressant medications (such as selective serotonin reuptake inhibitors or SSRIs). Regulatory documents indicate that the combination is associated with a potential increase in the risk of seizures and is a matter for professional review.


Q: Do studies suggest Tebonin Forte is more effective in certain age groups?

The medicine is indicated for adults aged 18 and above. Although the official indications primarily address symptoms related to age-related cognitive and circulatory disorders, regulatory documents do not provide specific comparative data on whether the extract is definitively more effective in one adult age range over another.


Q: Is it possible for Tebonin Forte to interact with herbal remedies?

Yes, interactions are possible with other herbal remedies. Official guidance advises against combining EGb 761 with herbal supplements that are known to have effects on blood clotting or thinning, such as garlic or ginseng. Combining such products may increase the potential risk of bleeding.


Q: Can Tebonin Forte be used for preventing age-related issues?

Regulatory indications focus on the treatment and management of existing symptoms related to neurosensory or age-associated cognitive decline. The extract is not officially indicated or approved for use as a form of primary prevention for age-related diseases in healthy individuals.


Q: Is the manufacturing process of Tebonin Forte regulated like other prescription drugs?

In countries where this preparation is classified as a medicine, its manufacturing is regulated to meet high pharmaceutical standards. The complex, standardized process for creating the EGb 761 extract ensures its quality, safety, and consistent concentration, which is a requirement for approved medicinal products.


Q: Are there any specific vitamins or supplements that should not be taken with Tebonin Forte?

Official product information recommends avoiding supplements that have blood-thinning effects due to the potential for increased bleeding risk. Examples of such supplements mentioned in interaction warnings include garlic and ginseng.


Q: Does Tebonin Forte affect sleep?

Official adverse reaction summaries for Ginkgo biloba preparations sometimes list sleep problems or insomnia as a possible effect. If a user experiences difficulty sleeping while taking this medicine, the experience should be noted for safety review.


Q: Is Tebonin Forte suitable for people who have high blood pressure?

Although high blood pressure (hypertension) is not listed as an absolute contraindication in product documents, official guidance advises that individuals with this condition are a matter for professional consultation before use.


Q: Can people with diabetes use Tebonin Forte?

The presence of diabetes itself is not listed as an absolute contraindication. However, official product information advises that individuals who are taking oral medications for diabetes are a matter for professional consultation due to potential interactions.


Q: What happens if I stop taking Tebonin Forte suddenly?

Official documents do not list specific withdrawal symptoms associated with suddenly stopping the medication. The general recommendation for treatment is a minimum course of at least eight weeks, suggesting that the benefits are achieved over time rather than immediately after starting or stopping.


Q: Is it necessary to have a prescription to get Tebonin Forte?

The availability and regulatory status vary significantly based on the country. In some regions, the EGb 761 preparation is classified as a non-prescription medicine available only in pharmacies, while in other areas, it may be sold as an over-the-counter dietary supplement.


Q: Can Tebonin Forte affect laboratory tests?

While general product information does not commonly list interference with routine laboratory tests, the extract's documented effect on blood clotting means monitoring of coagulation parameters (such as INR) is a consideration in clinical use, particularly when combined with other blood-thinning medicines.


Q: Are there warnings about driving or operating machinery while taking Tebonin Forte?

Official safety warnings state that due to the possibility of side effects such as dizziness and drowsiness, activities requiring full attention, such as driving or operating hazardous machinery, should be avoided until the user is aware of how the medicine affects them.


Q: Does alcohol consumption affect how Tebonin Forte works?

Official guidance on alcohol consumption with this preparation is often general. The general caution for Ginkgo preparations is to avoid or limit alcohol use, primarily because this may intensify nervous system side effects like dizziness and drowsiness.


Q: Does taking Tebonin Forte require regular blood tests or check-ups?

Specific, scheduled regular blood tests are not typically mandated for the medicine itself. However, official guidance emphasizes that any signs of bleeding should be reported, and professional review should be sought if symptoms do not show improvement within the recommended treatment period.


Q: Do health authorities classify Tebonin Forte differently depending on the country?

Yes, the classification of the standardized EGb 761 preparation varies significantly by country. Health authorities in certain regions classify it as an approved drug (medicine), while in others, it is regulated and sold as a dietary supplement.


Q: Is Tebonin Forte associated with causing anxiety or nervousness?

Regulatory documents list certain effects such as dizziness and heart palpitations as possible adverse reactions. Although not commonly listed as a direct side effect, any unexpected changes in mood or energy, such as nervousness, should be noted when reviewing safety information.

Advertisements

How should Tebonin Forte be stored and disposed of?

How to Store and Dispose of Tebonin Forte?

Tebonin Forte (EGb 761) must be stored under specific environmental constraints to maintain the stability of the standardized extract, as required by regulatory labeling.

Official Storage Requirements

The product must be stored at a temperature not exceeding 30°C and must be kept protected from both light and moisture. This ensures the stability of the film-coated tablets until the expiry date. It is a mandatory requirement to keep Tebonin Forte out of the sight and reach of children.

Disposal Instructions

Unused or expired Tebonin Forte must be disposed of according to local regulations. The official instructions require that the medicine must not be discarded into household wastewater or general household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tebonin Forte found in:

A-Z Index: